CA
RXST icon

Clearstead Advisors’s RxSight RXST Stock Holding History

Clearstead Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594 Buy
+123
New +$742 ﹤0.01% 2872
2025
Q4 		– Sell
-1
Closed -$9 – 3174
2025
Q3 		$9 Buy
+1
New +$9 ﹤0.01% 3049

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's RXST Position: Q2 2026 in Review

Clearstead Advisors opened a new position in RxSight (RXST) in Q2 2026: 123 shares worth $594. The stake represents ﹤0.01% of the portfolio and ranks #2872 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in RXST as recently as Q3 2025.

Clearstead Advisors first reported a position in RXST in Q3 2025 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Clearstead Advisors held 123 shares of RxSight worth $594 as of Q2 2026.
  • RxSight was a new Clearstead Advisors position in Q2 2026.
  • RxSight made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2872 holding.
  • Clearstead Advisors first reported a position in RxSight in Q3 2025 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.